STOCKHOLM, June 29, 2010 /PRNewswire/ — Today,
Karolinska Development has divested Cogmed, one of Karolinska
Development’s portfolio companies, to Pearson where it will become
part of Pearson’s Clinical Assessment business. Karolinska
Development and other owners will receive an up front payment, as
well as tiered royalties up to double digit levels until June 2012 on Cogmed sales. Karolinska
Development holds 51.83 percent of Cogmed. Pearson will take
possession on June 29, 2010.
The financial details of the acquisition have not been
disclosed.
Redwood Capital Group acted as exclusive financial advisor to
Cogmed in connection with the transaction.
TO THE EDITORS
About Karolinska Development
Karolinska Development manages one of the largest portfolios of
life science companies in Europe.
Using a unique, highly cost efficient business model, the
management team guides the commercialization of world class life
science innovations, helping to shape the next generation Pharma
industry. Since 2003, Karolinska Development has built a portfolio
of some 40 companies; among the company’s projects 12 compounds are
undergoing clinical trials. The portfolio contains a total of 21
potential first-in-class products. http://www.karolinskadevelopment.com
About Cogmed
Cogmed was founded in 2001. The company provides scien
‘/>”/>
SOURCE
